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Has preventive medicine entered the 
realm of the interventional cardiologist?
EDITORIAL
The result of the Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial(1) released at the 
recent ESC meeting held in Amsterdam has attracted enormous interest and rightly so: if the conclusions 
drawn by the researchers prove correct, the management of patients presenting with a ST segment 
elevation myocardial infarction (STEMI) is about to undergo a major change. The authors provide 
evidence to support “preventive PCI” in non-infarct related coronary arteries in patients with multivessel 
disease undergoing angiography with the objective of opening the infarct related coronary artery. These 
findings challenge the long-held view, reflected in international guidelines, that PCI in this setting should 
be aimed only at the so-called culprit lesion. It also challenges the view that the likelihood of atheromatous 
plaque rupture is primarily related to the properties of the plaque (degree of inflammation, cap thickness, 
cholesterol content) and not the degree of stenosis.
The trial enrolled 465 patients with acute STEMI who were undergoing infarct-artery related PCI. Patients 
were randomised to “preventive PCI” (234 patients; lesions of more than 50% stenosis in non-infarct 
related arteries were treated by PCI) or “no preventive PCI” (231 patients; lesions of more than 50% in 
non-infarct related arteries were present but only the culprit lesion was treated by PCI). The primary 
endpoint was a composite of death from cardiac causes, non-fatal myocardial infarction or refractory 
angina. The trial was stopped early (mean follow up 23 months) as the data and safety monitoring 
committee detected a clear advantage in the “preventive PCI” group (hazard ratio in the “preventive 
PCI” group, 0.35; P<0.001 which equates to an absolute risk reduction of 14%). The authors suggest 
that this study settles the debate regarding the best strategy for the management of patients presenting 
with a STEMI by establishing that “preventive PCI” is a better strategy than restricting further interven-
tion to patents presenting with refractory angina or a subsequent myocardial infarction. They concede 
that the strategy of delayed or staged PCI for lesions in non-culprit vessels had not been addressed 
in this study. They also pose the provocative question if the benefits of “preventive PCI” may extend 
to lesions less than 50% in non-culprit vessels.
Extrapolation of the findings of this study to the patients we manage in our practises every day without 
due consideration of all the available information may put our patients at risk. So what are the available 
facts? Patients presenting with a STEMI are at significant risk of suffering another myocardial infarction 
and/or dying from a cardiac cause. The determinants of this risk include the age and sex of the patient, 
the presence and the management of risk factors for coronary artery disease, location of the infarct 
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Editor, Anton Doubell (e.g. inferior vs anterior), size of the infarct and degree of impairment of left ventricular function. The 
authors state that “the results were not materially affected by… age, sex, the presence or absence of 
diabetes, infarct location or the number of coronary arteries with stenosis”. One cannot however ignore 
the fact that more patients in the group not receiving “preventive PCI” were diabetic (21% vs 15%) and 
more patients in this group suffered anterior myocardial infarctions (39% vs 29%). Diabetic patients have 
significantly worse outcomes compared to non-diabetic patients and the larger number of anterior 
infarcts may have led to more systolic dysfunction (an important determinant of outcome) in this group. 
Although the differences in infarct related artery between the “preventive PCI” and “non-preventive 
PCI” did not reach statistical significance it is conceivable that the resulting differences in left ventri-
cular ejection fraction (LVEF) did, and that the difference in LVEF between the two groups contributed 
to the difference in outcome. However this does not explain the higher infarction rate in patients where 
the non-culprit lesions were not treated as reported in this trial. The mechanism of this observation 
remains unexplained. The principle investigator has indicated that the subsequent infarctions occurred 
in the non-culprit vessels but it was not stated if the occlusions occurred at the untreated lesions or 
proximal or distal to these lesions. The lower infarction rate in patients who had the non-culprit lesions 
treated suggests that these lesions were the site of subsequent occlusions. However, altered flow 
proximal or distal to significant lesions, resulting in an alteration of endothelial function and subsequent 
risk of plaque rupture, may also be a plausible mechanism for a protective effect conferred by relieving 
the obstructions. The findings of this study have highlighted the fact that our knowledge of the mechanisms 
of plaque rupture leading to myocardial infarction is still incomplete.
To extrapolate the findings of this single trial to our everyday practices without further verification would 
be premature. It certainly would not be appropriate to use this trial as justification to generate full metal 
jacket coronary trees in our patients presenting with a STEMI, a scenario that is not far-fetched if you 
consider the view posed by the authors of the PRAMI trail that consideration must be given to treating 
non-culprit stenosis less than 50%. In patients with multivessel disease, decisions regarding further 
revascularisation would have to include the risk factor profile of the patient (e.g. diabetic vs non-diabetic), 
the location and size of the infarct being treated, the number, severity and complexity of non-culprit 
lesions (e.g. patients with high Syntax score vs low Syntax score; the FFR values vs visual estimates of 
lesions) as well as the relative advantages/disadvantages of ischaemia driven or deferred intervention 
strategies.
Let us assume that the findings of the PRAMI trial will be borne out by further studies designed to 
validate these findings. What is the explanation for this observation? In patients with stable angina 
protection against myocardial infarction and cardiac death is earned by good risk factor control and not 
by interventional revascularisation strategies. The reason for this is that protection is afforded by pacifying 
all the inflamed atheromatous plaques that could potentially rupture and lead to coronary occlusion. The 
majority of these plaques are non-obstructive and therefore a preventive strategy aimed at the obstructive 
lesions does not afford protection. To suggest that targeting the non-obstructive lesions in patients with 
stable angina, where most of the plaque burden would be non-inflamed and stable, would have no 
scientific basis and therefore no justification. Can we present a different case for the patient who presents 
with a STEMI? The plaque rupture that led to the infarct serves as a marker for the inflamed nature of 
the total plaque burden in these patients and one may reason that any number of the plaques in the rest 
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of the culprit vessel or in non-culprit vessels will be equally inflamed and potentially on the verge of 
rupture. Based on this argument PCI of non-culprit lesions may well confer protection. However, based 
on the knowledge that plaque rupture is not clearly linked to the degree of obstruction, one may assume 
that the protective advantage of stenting non-culprit lesions may be because it targets the sections of 
vessels with the highest plaque burden. Extrapolating this argument may well argue in favour of the 
full metal jacket approach to “preventive PCI” but any potential advantage of such a strategy is likely 
to be offset by the risks conferred by multiple and long stents. A future strategy of truly preventive 
stenting would have to be based on a better understanding of the pathogenesis of reinfarction and death 
following a STEMI and in particular a better selection of lesions likely to rupture, possibly by considering 
inherent properties of the plaque such as lipid content and cap thickness (detected by IVUS or OCT) 
or plaque inflammation (e.g. detected by assessing plaque temperature) in addition to the degree of 
stenosis. The PRAMI study should be valued not so much for the answer it has provided but for the 
questions it has raised.
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